Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis

• Main Authors: Attapon Cheepsattayakorn, Ruangrong Cheepsattayakorn
• Format: Journal
• Published: 2018
• Subjects: Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84863919123&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/51865
• Institution: Chiang Mai University

A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide. © 2012 Bentham Science Publishers.